BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 9778279)

  • 21. Adductor muscle activity abnormalities in abductor spasmodic dysphonia.
    Cyrus CB; Bielamowicz S; Evans FJ; Ludlow CL
    Otolaryngol Head Neck Surg; 2001 Jan; 124(1):23-30. PubMed ID: 11228447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Voice analysis in adductor spasmodic dysphonia: Objective diagnosis and response to botulinum toxin.
    Suppa A; Asci F; Saggio G; Marsili L; Casali D; Zarezadeh Z; Ruoppolo G; Berardelli A; Costantini G
    Parkinsonism Relat Disord; 2020 Apr; 73():23-30. PubMed ID: 32222482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment efficacy of electromyography versus fiberscopy-guided botulinum toxin injection in adductor spasmodic dysphonia patients: a prospective comparative study.
    Kim JW; Park JH; Park KN; Lee SW
    ScientificWorldJournal; 2014; 2014():327928. PubMed ID: 25383369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
    Hogikyan ND; Wodchis WP; Spak C; Kileny PR
    J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Life Threatening Delayed Complication of Botulinum Toxin Injection for Treatment of Spasmodic Dysphonia.
    Yershov D; Partridge R
    Prague Med Rep; 2020; 121(2):114-117. PubMed ID: 32553095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of patient factors on response outcomes to Botox treatment of spasmodic dysphonia.
    Lundy DS; Lu FL; Casiano RR; Xue JW
    J Voice; 1998 Dec; 12(4):460-6. PubMed ID: 9988033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.
    Troung DD; Rontal M; Rolnick M; Aronson AE; Mistura K
    Laryngoscope; 1991 Jun; 101(6 Pt 1):630-4. PubMed ID: 2041443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Mayo Clinic Arizona Spasmodic Dysphonia Experience: A Demographic Analysis of 718 Patients.
    Patel AB; Bansberg SF; Adler CH; Lott DG; Crujido L
    Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):859-63. PubMed ID: 26024910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum toxin therapy for abductor spasmodic dysphonia.
    Woodson G; Hochstetler H; Murry T
    J Voice; 2006 Mar; 20(1):137-43. PubMed ID: 16126369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia.
    Holzer SE; Ludlow CL
    Laryngoscope; 1996 Jan; 106(1 Pt 1):86-92. PubMed ID: 8544635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
    van Esch BF; Wegner I; Stegeman I; Grolman W
    Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spasmodic Dysphonia.
    Lin J; Sadoughi B
    Adv Otorhinolaryngol; 2020; 85():133-143. PubMed ID: 33166970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgery or botulinum toxin for adductor spasmodic dysphonia: a comparative study.
    Mendelsohn AH; Berke GS
    Ann Otol Rhinol Laryngol; 2012 Apr; 121(4):231-8. PubMed ID: 22606926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia.
    Blitzer A
    Otolaryngol Head Neck Surg; 2005 Dec; 133(6):836-8. PubMed ID: 16360499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transoral electromyographic recordings in botulinum toxin-injected rat larynges.
    Inagi K; Rodriquez AA; Ford CN; Heisey DM
    Ann Otol Rhinol Laryngol; 1997 Nov; 106(11):956-64. PubMed ID: 9373087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
    Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
    Kendall KA; Leonard RJ
    J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of botulinum toxin type A injections on aerodynamic measures of spasmodic dysphonia.
    Adams SG; Durkin LC; Irish JC; Wong DL; Hunt EJ
    Laryngoscope; 1996 Mar; 106(3 Pt 1):296-300. PubMed ID: 8614192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results.
    Adams SG; Hunt EJ; Charles DA; Lang AE
    J Otolaryngol; 1993 Jun; 22(3):171-5. PubMed ID: 8371328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.